Compare Charles River Laboratories Intl. Inc (CRL) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Equinix Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $228.74 (market cap $11.14B), while Equinix Inc trades at $1,014.28 (market cap $100.95B). The key difference: Equinix Inc is far larger — about 9.1× Charles River Laboratories Intl. Inc's market cap, and Equinix Inc pays a 1.92% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | EQIX | |
|---|---|---|
Market Cap | $11.14B | $100.95B |
Sector | Health | Real Estate |
52-Week High | $233.60 | $1.12K |
52-Week Low | $145.57 | $726.09 |
Enterprise Value | $14.00B | $121.23B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
EQIX trades at $1,039.53, down 1.11% on the day, with a bullish technical signal and strong analyst support (74.51% buy ratings). Revenue grew to $9.22B in 2025, with net income reaching $1.35B, though recent quarters showed mixed earnings results. The company benefits from AI infrastructure demand, evidenced by partnerships with Cisco and NVIDIA (Business Wire, 2026-06-17).
Outlook remains positive due to recurring revenue growth and AI tailwinds, but high valuation (P/E 71.89) and negative cash flow (-$1.26B in 2025) pose risks. Debt levels are rising, with debt-to-asset ratio at 47.13% in 2025. The consensus price target of $1,110 suggests upside potential if execution aligns with AI-driven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
